News Releases

The latest news releases from Fresenius Medical Care North America

For media inquiries, please contact or 781-699-5280

FMCNA Renews Partnership with NKF to Support People Affected by Kidney Disease

published March 27, 2019

For the second year, Fresenius Medical Care North America (FMCNA), the largest provider of dialysis products and services, will serve as National Presenting Sponsor for the National Kidney Foundation’s 2019 Kidney Walks. As part of that commitment, the company will rally employees for a National Team in an attempt to exceed their record participation in 2018, which brought thousands of employees and their families out to support people affected by kidney disease.

Fresenius Medical Care Announces Creation of Global Medical Office

published March 20, 2019

Fresenius Medical Care, the world’s largest provider of dialysis products and services, announced today that it has appointed Dr. Frank Maddux as Global Chief Medical Officer and Dr. Robert Kossmann as Chief Medical Officer for North America. In addition, Dr. Jeffrey Hymes, Chief Medical Officer for Fresenius Kidney Care, will expand his role to also serve as Senior Vice President of Clinical and Scientific Affairs for Fresenius Medical Care North America.

FDA Grants Breakthrough Device Designation to FMCNA’s Software for Fluid Management During Hemodialysis

published March 14, 2019

Fresenius Medical Care North America’s Renal Therapies Group, the leading provider of kidney care products, announced today that the U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to its computer-assisted ultrafiltration (UF) control software currently in development to improve fluid management during hemodialysis and personalize treatments.

FMCNA Celebrates National Kidney Month with Donations to Support Educational Efforts

published March 4, 2019

Fresenius Medical Care North America (FMCNA), the nation’s leading provider of kidney care products and services, has announced a 2019 commitment of $195,000 to support nonprofit patient education programs that help people with chronic kidney disease (CKD) make informed treatment choices including transplant and home dialysis.

Fresenius Medical Care Completes Acquisition of NxStage Medical

published February 26, 2019

Fresenius Medical Care has successfully completed the acquisition of NxStage Medical, Inc., which develops, produces and markets an innovative product portfolio of medical devices for use in home dialysis and critical care. The acquisition will enable Fresenius Medical Care to leverage its manufacturing, supply chain and marketing competencies across the dialysis products, services and Care Coordination businesses in a less labor- and capital-intensive care setting.

FMCNA Launches 2008T BlueStar™ Hemodialysis Machine Across the U.S.

published February 11, 2019

Fresenius Medical Care North America’s Renal Therapies Group today announced market availability of the 2008T BlueStar™ hemodialysis machine. With evolved technologies and elevated performance across more than 30 unique enhancements, the 2008T BlueStar machine represents the most comprehensive upgrade in company history.

FMCNA Raises $800,000 For Kidney Disease Awareness and Prevention Through Kidney Walks

published December 12, 2018

Fresenius Medical Care North America (FMCNA), the world’s largest provider of dialysis products and services, raised more than $800,000 for the National Kidney Foundation (NKF) centerpiece Kidney Walk fundraiser, the nation’s largest fundraising initiative to fight kidney disease. The company, which served as National Presenting Sponsor, bested its own record set last year by more than $100,000, raising the most ever by a National Team.

Lower Hospitalization Rates Observed Among Patients New to Hemodialysis with RBV-M Utilizing Crit-Line®

published October 26, 2018

Fresenius Medical Care’s Renal Therapies Group today announced the results of four studies utilizing the Crit-Line® monitor that examine how relative blood volume monitoring (RBV-M) can help improve patient outcomes. All four abstracts were accepted for poster presentation at the 2018 American Society of Nephrology’s (ASN) Kidney Week Symposium in San Diego, Calif.